However, in the larger substudy of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS), targeting interleukin-1β (IL-1β) did not result in better glycemic control or a reduction in the incidence of new-onset T2DM (11). Here, IL1B is linked to type 2 diabetes mellitus.